Fulcrum Therapeutics
FULC
105 hedge funds and large institutions have $422M invested in Fulcrum Therapeutics in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 38 increasing their positions, 23 reducing their positions, and 21 closing their positions.
1,553% more call options, than puts
Call options by funds: $5.16M | Put options by funds: $312K
114% more capital invested
Capital invested by funds: $197M → $422M (+$225M)
65% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 23
19% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 21
5.2% more ownership
Funds ownership: 97.93% → 103.13% (+5.2%)
4% more funds holding
Funds holding: 101 → 105 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$50.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$12M |
| 3 |
VA
VR Adviser
New York
|
+$8.59M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.52M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$5.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.54M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$1.74M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.55M |
| 4 |
Two Sigma Investments
New York
|
-$1.05M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$917K |
FULC Hedge Fund Activity: Q3 2022 in Review
105 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q3 2022, worth a combined $422M — up 114% from $197M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new FULC positions and 21 closed out — a net gain of 4 holders — while 38 added to existing stakes and 23 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $50.1M. The largest seller was Point72 Asset Management, cutting an estimated $3.54M.
- 105 institutional investors held Fulcrum Therapeutics (FULC) as of Q3 2022, up from 101 in Q2 2022.
- Funds reported $422M of Fulcrum Therapeutics stock for Q3 2022, up 114% quarter-over-quarter.
- 25 funds opened new Fulcrum Therapeutics positions in Q3 2022 and 21 closed out, a net change of +4 holders.
- The largest Fulcrum Therapeutics buyer in Q3 2022 was RA Capital Management, an estimated $50.1M added.
- The largest Fulcrum Therapeutics seller in Q3 2022 was Point72 Asset Management, an estimated $3.54M sold.
Based on aggregated 13F filings for Q3 2022.